David Shaw’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $62.6M | Sell |
1,605,994
-70,719
| -4% | -$2.28M | 0.03% | 651 |
|
|
2026
Q1 | $54.6M | Sell |
1,676,713
-41,780
| -2% | -$1.34M | 0.03% | 624 |
|
|
2025
Q4 | $60.5M | Buy |
1,718,493
+1,557,136
| +965% | +$55.2M | 0.03% | 618 |
|
|
2025
Q3 | $4.24M | Sell |
161,357
-44,116
| -21% | -$1.32M | ﹤0.01% | 2356 |
|
|
2025
Q2 | $5.45M | Sell |
205,473
-120,821
| -37% | -$3.18M | ﹤0.01% | 1972 |
|
|
2025
Q1 | $7.88M | Buy |
326,294
+224,051
| +219% | +$7.08M | 0.01% | 1567 |
|
|
2024
Q4 | $4.11M | Sell |
102,243
-354,217
| -78% | -$20.2M | ﹤0.01% | 2137 |
|
|
2024
Q3 | $28.9M | Sell |
456,460
-69,042
| -13% | -$4.05M | 0.02% | 782 |
|
|
2024
Q2 | $27.9M | Buy |
525,502
+449,760
| +594% | +$29.5M | 0.03% | 718 |
|
|
2024
Q1 | $6.21M | Sell |
75,742
-39,893
| -34% | -$1.78M | 0.01% | 1722 |
|
|
2023
Q4 | $2.15M | Buy |
115,635
+29,655
| +34% | +$388K | ﹤0.01% | 2613 |
|
|
2023
Q3 | $952K | Sell |
85,980
-244,942
| -74% | -$3.5M | ﹤0.01% | 3092 |
|
|
2023
Q2 | $5.36M | Sell |
330,922
-519,133
| -61% | -$10.9M | 0.01% | 1816 |
|
|
2023
Q1 | $14.2M | Sell |
850,055
-101,185
| -11% | -$1.05M | 0.02% | 1113 |
|
|
2022
Q4 | $8.94M | Buy |
951,240
+937,374
| +6,760% | +$4.18M | 0.01% | 1544 |
|
|
2022
Q3 | $38K | Sell |
13,866
-3,434
| -20% | -$11.2K | ﹤0.01% | 4715 |
|
|
2022
Q2 | $50K | Sell |
17,300
-158,978
| -90% | -$393K | ﹤0.01% | 4844 |
|
|
2022
Q1 | $529K | Buy |
+176,278
| New | +$632K | ﹤0.01% | 4338 |
|
|
2021
Q3 | – | Sell |
-16,273
| Closed | -$97K | – | 5256 |
|
|
2021
Q2 | $97K | Sell |
16,273
-2,966
| -15% | -$17.6K | ﹤0.01% | 4556 |
|
|
2021
Q1 | $122K | Sell |
19,239
-5,526
| -22% | -$38.9K | ﹤0.01% | 3913 |
|
|
2020
Q4 | $139K | Sell |
24,765
-34,492
| -58% | -$209K | ﹤0.01% | 3779 |
|
|
2020
Q3 | $345K | Sell |
59,257
-15,260
| -20% | -$105K | ﹤0.01% | 3379 |
|
|
2020
Q2 | $537K | Buy |
74,517
+3,719
| +5% | +$24.7K | ﹤0.01% | 3320 |
|
|
2020
Q1 | $331K | Buy |
70,798
+57,257
| +423% | +$352K | ﹤0.01% | 3421 |
|
|
2019
Q4 | $109K | Buy |
+13,541
| New | +$98.7K | ﹤0.01% | 3870 |
|
|
2018
Q4 | – | Sell |
-27,426
| Closed | -$478K | – | 4009 |
|
|
2018
Q3 | $478K | Sell |
27,426
-74,420
| -73% | -$886K | ﹤0.01% | 3140 |
|
|
2018
Q2 | $967K | Buy |
+101,846
| New | +$677K | ﹤0.01% | 2724 |
|
Other funds holding VKTX
David Shaw's VKTX Position: Q2 2026 in Review
David Shaw reduced its Viking Therapeutics (VKTX) stake by 4.2% in Q2 2026, selling an estimated $2.28M and leaving 1,605,994 shares worth $62.6M. The position accounts for 0.03% of the portfolio, ranked #651.
David Shaw first reported a position in VKTX in Q2 2018 and has held it in 27 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.
- David Shaw held 1,605,994 shares of Viking Therapeutics worth $62.6M as of Q2 2026.
- David Shaw sold 70,719 Viking Therapeutics shares in Q2 2026, an estimated $2.28M.
- Viking Therapeutics made up 0.03% of David Shaw's portfolio in Q2 2026, its #651 holding.
- David Shaw first reported a position in Viking Therapeutics in Q2 2018 and has held it in 27 quarters since.
- 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.
Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.